Clinical Trial

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

Study acronym: UPRISE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2029-11-01 -> 2030-03-01 2026-06-10
minor Completion pushed: 2029-11-01 -> 2030-03-01 2026-06-10
Trial Details
NCT Number NCT07526545
Lead Sponsor University of Michigan Rogel Cancer Center
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)
Conditions Prostate Carcinoma
Enrollment 800 participants
Start Date 2026-09-01
Primary Completion 2030-03-01 (estimated)
Study Completion 2030-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-09